Hologic (HOLX) Projected to Post Quarterly Earnings on Thursday

Hologic (NASDAQ:HOLX) is anticipated to release its Q1 2026 results after the market closes on Thursday, January 29th. Analysts expect Hologic to post earnings of $1.09 per share and revenue of $1.0734 billion for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.Hologic’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.01 EPS. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Trading Up 0.2%

Shares of HOLX stock opened at $75.19 on Tuesday. The business has a 50-day moving average of $74.82 and a 200 day moving average of $70.66. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. Hologic has a 1-year low of $51.90 and a 1-year high of $75.34. The stock has a market capitalization of $16.79 billion, a PE ratio of 30.32, a P/E/G ratio of 2.13 and a beta of 0.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors lifted its position in Hologic by 6.1% during the second quarter. Captrust Financial Advisors now owns 15,933 shares of the medical equipment provider’s stock valued at $1,038,000 after buying an additional 910 shares during the period. Corient Private Wealth LLC grew its position in shares of Hologic by 14.7% in the 2nd quarter. Corient Private Wealth LLC now owns 53,095 shares of the medical equipment provider’s stock worth $3,460,000 after buying an additional 6,820 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Hologic by 40.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,048 shares of the medical equipment provider’s stock worth $264,000 after acquiring an additional 1,157 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in Hologic by 23.1% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 351,042 shares of the medical equipment provider’s stock valued at $22,903,000 after acquiring an additional 65,848 shares during the period. Finally, Parallel Advisors LLC boosted its stake in Hologic by 8.9% during the third quarter. Parallel Advisors LLC now owns 2,950 shares of the medical equipment provider’s stock worth $199,000 after acquiring an additional 242 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HOLX. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 target price on shares of Hologic in a report on Wednesday, October 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Leerink Partners increased their target price on shares of Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a report on Tuesday, October 21st. Finally, Morgan Stanley raised their target price on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $79.31.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.